重度子痫前期胎盘microRNA谱差异表达研究 [中文引用][英文引用]

目的 筛选云南地区重度子痫前期孕妇与正常孕妇胎盘组织中microRNA差异表达，探究microRNA与重度子痫前期发病机制的关系。方法 通过对3例重度子痫前期患者和3例正常孕妇胎盘组织抽提Total RNA样品检测，Small RNA Sample Pre Kit文库构建，上机行HiSeq测序，获得microRNA的表达数据。对差异表达的microRNA进行差异分析、靶基因预测、靶基因注释等生物信息学分析。结果 通过对实验组与对照组microRNA表达谱的对比，筛选出了41个差异表达的microRNA，其中22个表达上调，19个表达下调。对候选靶基因KEGG富集最显著的20条分析结果显示：候选靶基因功能富集通路与Rap1信号通路、雌激素信号通路、焦点黏着、FcγR介导的吞噬作用、调节干细胞多能性的信号通路、钙信号通路、炎症介质调节的TRP通道、Ras信号通路、TGF-β信号通路的炎症介质调节等相关。结论 重度子痫前期与正常产妇胎盘组织存在差异表达的microRNA，可能与重度子痫前期的发病机制相关，胎盘组织中差异表达的microRNA为探寻新的重度子痫前期诊断标记物及潜在治疗靶点提供依据。

Objective To screen the differential expression of microRNA in placenta of pregnant women with severe preeclampsia and normal pregnant women in Yunnan and explore the relationship between microRNA and pathogenesis of severe preeclampsia. Methods Total RNA was extracted from placentas of 3 severe preeclampsia patients and 3 normal pregnant women. The small RNA Sample Pre Kit library was constructed and sequenced by HiSeq. The differentially expressed microRNAs were analyzed by bioinformatics such as differential analysis, target gene prediction and target gene annotation. Results By comparing the microRNA expression profiles of the experimental group and the control group, 41 differentially expressed microRNAs were screened out, of which 22 were up-regulated and 19 down-regulated. The 20 most significant analysis results of KEGG enrichment showed that the candidate target gene enrichment pathway was associated with Rap1 signaling pathway, estrogen signaling pathway, focal adhesion, Fc-gamma R-mediated phagocytosis, signal pathway regulating stem cell pluripotency, calcium signaling pathway, TRP pathway regulated by inflammatory mediators, and Ras signaling pathway. The TGF- beta signaling pathway is mediated by inflammatory mediators. Conclusions Differentially expressed microRNA in placenta of preeclampsia women may be related to the pathogenesis of severe preeclampsia. Differentially expressed microRNA in placenta may provide a basis for exploring new diagnostic markers and potential therapeutic targets for severe preeclampsia.